Aspire Biopharma Holdings, Inc.是一家專注於開發和營銷創新的舌下給藥機制的公司，針對已知藥物和補充劑，已發佈其第三季度的 10-Q 報告。該報告詳細概述了公司的財務表現和業務運營，反映了其早期階段的狀態以及不斷擴展市場存在的努力。
財務亮點
<ul>
<li>淨收入：$1,941 - 公司在此期間報告的收入極少，表明處於早期運營階段。</li>
<li>毛利潤：$884 - 反映了產品銷售的初始階段，盈利能力有限。</li>
<li>運營損失：$(17,501,867) - 公司經歷了顯著的運營損失，主要由於高額的管理和行政費用，包括基於股票的補償。</li>
<li>淨虧損：$(19,773,114) - 大額淨虧損歸因於高額的運營費用和利息費用。</li>
<li>普通股基本和稀釋每股淨虧損：$(0.43) - 反映了淨虧損對股東的影響。</li>
</ul>
業務亮點
<ul>
<li>收入細分：公司報告了來自營養保健產品的收入，銷售主要發生在美國，少部分在加拿大。這表明其產品分銷主要集中在北美市場。</li>
<li>地域表現：大部分銷售集中在美國，佔總收入的$1,901，加拿大貢獻$40。這表明公司在國內市場的強大存在，國際市場的覆蓋有限。</li>
<li>新產品發佈：Aspire Biopharma Holdings, Inc.專注於開發和營銷顛覆性技術，針對新型舌下給藥機制，最初目標是已知藥物和補充劑，如阿司匹林和咖啡因產品。這表明公司在製藥和補充劑行業內持續創新的努力。</li>
<li>未來展望：公司計劃繼續專注於擴大銷售和營銷努力，以及研究和開發活動。然而，公司承認需要額外融資來支持這些計劃，這可能涉及通過股權發行籌集資金。</li>
</ul>
SEC 文件：Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q -2025 年 11 月 14 日

ASBP

Aspire Biopharma Holdings, Inc. 發佈了其第三季度的 10-Q 報告，報告顯示收入僅為 1,941 美元，淨虧損高達 19,773,114 美元。該公司專注於藥物和補充劑的舌下給藥機制，絕大多數銷售在美國。未來計劃包括擴大銷售、市場營銷和研發，這需要額外的融資

Aspire Biopharma Holdings, Inc., a company focused on developing and marketing innovative sublingual delivery mechanisms for known drugs and supplements, has released its Form 10-Q report for the third quarter. The report provides a detailed overview of the company's financial performance and business operations, reflecting its early-stage status and ongoing efforts to expand its market presence.
<div class="lb-trans">Aspire Biopharma Holdings, Inc.是一家專注於開發和營銷創新的舌下給藥機制的公司，針對已知藥物和補充劑，已發佈其第三季度的 10-Q 報告。該報告詳細概述了公司的財務表現和業務運營，反映了其早期階段的狀態以及不斷擴展市場存在的努力。
</div>Financial Highlights
<div class="lb-trans">財務亮點
</div><ul>
<li>Net Revenue: $1,941 - The company reported minimal revenue for the period, indicating early-stage operations.</li>
<li>Gross Profit: $884 - Reflects the initial stages of product sales with limited profitability.</li>
<li>Loss from Operations: $(17,501,867) - The company experienced significant operating losses, primarily due to high general and administrative expenses, including stock-based compensation.</li>
<li>Net Loss: $(19,773,114) - The substantial net loss is attributed to high operating expenses and interest expenses.</li>
<li>Basic and diluted net loss per share of Common Stock: $(0.43) - Reflects the impact of the net loss on shareholders.</li>
</ul>
<div class="lb-trans"><ul>
<li>淨收入：$1,941 - 公司在此期間報告的收入極少，表明處於早期運營階段。</li>
<li>毛利潤：$884 - 反映了產品銷售的初始階段，盈利能力有限。</li>
<li>運營損失：$(17,501,867) - 公司經歷了顯著的運營損失，主要由於高額的管理和行政費用，包括基於股票的補償。</li>
<li>淨虧損：$(19,773,114) - 大額淨虧損歸因於高額的運營費用和利息費用。</li>
<li>普通股基本和稀釋每股淨虧損：$(0.43) - 反映了淨虧損對股東的影響。</li>
</ul>
</div>Business Highlights
<div class="lb-trans">業務亮點
</div><ul>
<li>Revenue Segments: The company reported revenue from nutraceutical products, with sales primarily occurring in the USA and a small portion in Canada. This indicates a focus on the North American market for its product distribution.</li>
<li>Geographical Performance: The majority of sales were concentrated in the USA, accounting for $1,901 of the total revenue, with Canada contributing $40. This suggests a strong domestic market presence with limited international reach.</li>
<li>New Product Launches: Aspire Biopharma Holdings, Inc. is focused on developing and marketing disruptive technology for novel sublingual delivery mechanisms, initially targeting known drugs and supplements such as aspirin and caffeine products. This indicates ongoing efforts to innovate within the pharmaceutical and supplements industry.</li>
<li>Future Outlook: The company plans to continue its focus on expanding sales and marketing efforts, as well as research and development activities. However, it acknowledges the need for additional financing to support these initiatives, which may involve raising capital through equity issuances.</li>
</ul>
<div class="lb-trans"><ul>
<li>收入細分：公司報告了來自營養保健產品的收入，銷售主要發生在美國，少部分在加拿大。這表明其產品分銷主要集中在北美市場。</li>
<li>地域表現：大部分銷售集中在美國，佔總收入的$1,901，加拿大貢獻$40。這表明公司在國內市場的強大存在，國際市場的覆蓋有限。</li>
<li>新產品發佈：Aspire Biopharma Holdings, Inc.專注於開發和營銷顛覆性技術，針對新型舌下給藥機制，最初目標是已知藥物和補充劑，如阿司匹林和咖啡因產品。這表明公司在製藥和補充劑行業內持續創新的努力。</li>
<li>未來展望：公司計劃繼續專注於擴大銷售和營銷努力，以及研究和開發活動。然而，公司承認需要額外融資來支持這些計劃，這可能涉及通過股權發行籌集資金。</li>
</ul>
</div>SEC Filing: Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q - Nov. 14, 2025
<div class="lb-trans">SEC 文件：Aspire Biopharma Holdings, Inc. [ ASBP ] - 10-Q -2025 年 11 月 14 日
</div>

Aspire Biopharma Holdings, Inc. 的 SEC 10-Q 報告